We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




NIV Test to Diagnose and Monitor Vascular Complications in Diabetes

By LabMedica International staff writers
Posted on 07 Oct 2019
Print article
Image: A ball-and-stick model of the 5-hydroxymethylcytosine (5hmC) molecule (Photo courtesy of Wikimedia Commons).
Image: A ball-and-stick model of the 5-hydroxymethylcytosine (5hmC) molecule (Photo courtesy of Wikimedia Commons).
By applying a sensitive test for analysis of DNA taken from patients with Type II diabetes, researchers were able to diagnose and monitor the presence and severity of diabetic vascular complications such as heart disease, atherosclerosis, and kidney failure.

About two-thirds of the 424 million diabetic patients worldwide die from vascular complications. Therefore, a clinically convenient, noninvasive approach for monitoring the development of these complications would improve the overall life quality of patients with Type II diabetes and help reduce healthcare burden through preventive interventions.

Investigators at Northwestern University (Chicago, IL, USA) had demonstrated previously that 5-hydroxymethylcytosine (5hmC), a relative stable intermediate product of active DNA demethylation, played a critical role in gene expression regulation and was also regarded as a novel epigenetic biomarker for cancer diagnosis and prognosis. They had invented TAB-seq, a method that could map 5hmC at base-resolution genome-wide, as well as hmC-Seal, a method that covalently labeled 5hmC for its detection. Furthermore, they introduced a sensitive and robust 5hmC sequencing approach which allowed genome-wide profiling of 5hmC using a limited amount of genomic DNA that could be readily isolated from only about 1,000 cells (nano-hmC-Seal).

The investigators applied this method to analyze three to five milliliter blood samples obtained from 62 diabetic patients (12 patients without vascular complications, 34 patients with a singular vascular complication, and 16 with multiple vascular complications).

Results revealed statistically significant changes in 5hmC markers associated with Type II diabetes-related macrovascular/microvascular complications, involving genes and pathways relevant to vascular biology and diabetes, including insulin resistance and inflammation. A 16-gene 5hmC marker panel accurately distinguished patients with vascular complications from those without, outperforming conventional clinical variables such as urinary albumin. In addition, a separate 13-gene 5hmC marker panel could distinguish patients with single complications from those with multiple complications, showing superiority over conventional clinical variables.

"We are very excited to apply our earlier findings in cancer patients to diabetic patients," said contributing author Dr. Wei Zhang, associate professor of cancer epidemiology and prevention at Northwestern University. "This discovery is going to revolutionize how quickly and non-invasively we can identify potentially fatal complications in the hundreds of millions of diabetic patients worldwide."

The work was published in the October 1, 2019, online edition of the journal Clinical Chemistry.

Related Links:
Northwestern University

Gold Supplier
Desktop Urine Analyzer
MONOZYME TX2000
New
POC RT-PCR COVID-19 Testing Platform
Convergys POC RT-PCR COVID-19 Testing Platform
New
Photometer
RIELE Photometer 505
New
5-Part Differential Hematology Analyzer
DxH 690T

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Illustration

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more

Hematology

view channel
Image: Bone marrow aspirate from a patient with Acute Myeloid Leukemia: Blasts are the predominant population and have a high nuclear to cytoplasmic ratio and generally lack granules. (Photo courtesy of Professor Peter G. Maslak, MD)

Cord Blood and Matched Related Donor Transplantation Compared in Acute Myeloid Leukemia

The prognosis of primary refractory and relapsed acute myeloid leukemia is poor, with a five-year overall survival of less than 10%. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only... Read more

Industry

view channel
Illustration

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.